

SCHEDULE 1

MARKETING AUTHORISATIONS

PART 2

Derogations from some of the requirements in Part 1

Scope

6. This Part provides for applications for marketing authorisations in which not all the information required in Part 1 is required, but for the avoidance of doubt any applicant may apply for a marketing authorisation using Part 1 if he wishes to do so.

Commencement Information

I1 Sch. 1 para. 6 in force at 1.10.2006, see [reg. 1](#)

Bibliographic application

7.—(1) An applicant for a marketing authorisation need not provide the results of safety tests, residue tests, pre-clinical trials or clinical trials if the active substance of the veterinary medicinal product has been in an authorised veterinary medicinal product for that species in the Community for at least ten years, and the applicant provides appropriate scientific literature to demonstrate this.

(2) He may use any publicly available document.

(3) If an applicant makes use of scientific literature to obtain authorisation for a food-producing species, and submits, in respect of the same medicinal product and with a view to obtaining authorisation for another food-producing species, new residue studies, together with further clinical trials, a third party may not use those studies or trials in an application for a pharmacologically equivalent product for a period of three years from the grant of the authorisation for the additional species.

Commencement Information

I2 Sch. 1 para. 7 in force at 1.10.2006, see [reg. 1](#)

Application for a product using a new combination of active substances

8. If an application is for a veterinary medicinal product containing active substances already used in an authorised veterinary medicinal product but not previously used in that combination in a veterinary medicinal product, he need not provide the safety and efficacy data for the individual active substances.

Commencement Information

I3 Sch. 1 para. 8 in force at 1.10.2006, see [reg. 1](#)

Application using existing data

9. If the Secretary of State has granted a marketing authorisation, the holder may permit him to use data submitted in support of that marketing authorisation when assessing an application for another marketing authorisation.

Commencement Information

I4 Sch. 1 para. 9 in force at 1.10.2006, see [reg. 1](#)

Application for a pharmacologically equivalent medicinal product

10.—(1) An applicant need not provide the results of safety tests, residue tests, pre-clinical trials or clinical trials if he can demonstrate that the veterinary medicinal product is pharmacologically equivalent to a veterinary medicinal product already authorised in the Community.

(2) For the purposes of this paragraph a product is pharmacologically equivalent to an existing product if—

- (a) it has the same qualitative and quantitative composition in active substances;
- (b) it has the same pharmaceutical form; and
- (c) bioequivalence has been demonstrated by means of appropriate bioavailability studies.

(3) For the purposes of this paragraph—

- (a) the different salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives of an active substance shall be considered to be the same active substance, unless they differ significantly in properties with regard to safety or efficacy; and
- (b) if they do differ significantly in properties with regard to efficacy or safety, additional information intended to provide proof of the safety or efficacy of the various salts, esters or derivatives of an authorised active substance must be supplied by the applicant.

(4) Different immediate-release oral pharmaceutical forms are regarded as the same pharmaceutical form.

(5) Bioavailability studies are not required if the bioequivalence guidelines produced by the Agency exempt the product.

(6) In the case of a reference product authorised in another member State but not in the United Kingdom, the Secretary of State must be satisfied that the risk-benefit balance of the original product is appropriate for the product to be placed on the market in the United Kingdom, and if the data provided under Article 13, third paragraph of Directive [2001/82/EC](#) by the member State in which the product is authorised are insufficient for him to be satisfied of this, he may notify the applicant and require the applicant to provide further data.

Commencement Information

I5 Sch. 1 para. 10 in force at 1.10.2006, see [reg. 1](#)

Time limits for marketing authorisations granted under the procedure for a pharmacologically equivalent product

11.—(1) This paragraph establishes the time limits relating to granting a marketing authorisation under the procedure for a pharmacologically equivalent product.

(2) An application for a marketing authorisation cannot be made until two years before the product may be placed on the market in accordance with this paragraph.

(3) The product shall not be placed on the market until ten years (or, in the case of medicinal products for fish or bees where the application for a marketing authorisation was submitted after 30th October 2005, thirteen years) have elapsed from the initial authorisation of the reference product.

(4) Time limits in this paragraph shall be calculated from the first grant of the marketing authorisation for the reference product.

Commencement Information

I6 Sch. 1 para. 11 in force at 1.10.2006, see [reg. 1](#)

Extension of time limits

12.—(1) This paragraph applies in relation to veterinary medicinal products that—

- (a) are intended for administration to food-producing species, and
- (b) contain a new active substance that was not authorised in the Community by 30th April 2004.

(2) If a person submits an application for a marketing authorisation for a product on or after 30th October 2005, and within 5 years of the original marketing authorisation being granted, the marketing authorisation is extended to include additional food-producing species, the ten-year period provided for in paragraph 11 shall be extended by one year for each additional food-producing species added to the marketing authorisation.

(3) The total period shall not exceed 13 years.

(4) The extension applies only if the marketing authorisation holder originally applied for determination of the maximum residue limits for the active substance.

Commencement Information

I7 Sch. 1 para. 12 in force at 1.10.2006, see [reg. 1](#)

Parallel imports

13.—(1) The Secretary of State may grant a marketing authorisation in relation to a veterinary medicinal product authorised in another member State and imported into the United Kingdom from that member State in accordance with this paragraph without the data required in Part 1 if the applicant can demonstrate compliance with this paragraph.

(2) If the product is for a food-producing species it must be identical to a product authorised in the United Kingdom.

(3) Other products must be therapeutically the same as a product authorised in the United Kingdom unless the importer can justify any differences.

(4) The member State from which it is imported must have authorised the product in accordance with Directive [2001/82/EC](#).

(5) The applicant must be established within the Community.

(6) The applicant must hold (or have a contract with the holder of) a wholesale dealer's authorisation in the United Kingdom appropriate to the type of product to be imported.

(7) If re-labelling is to take place in the United Kingdom the applicant must also be (or have a contract with) the holder of a suitable manufacturing authorisation in the United Kingdom.

Commencement Information

I8 Sch. 1 para. 13 in force at 1.10.2006, see [reg. 1](#)

Specific batch control scheme

14.—(1) Where a veterinary medicinal product (other than a biological veterinary medicinal product) has been granted a marketing authorisation or an animal test certificate, and any starting material (active substance, excipient or packaging) or any batch of the product does not fully meet the requirements of the authorisation or animal test certificate, the holder may apply to the Secretary of State to place one or more batches on the market notwithstanding this.

(2) The Secretary of State may authorise the placing on the market if he is satisfied that the safety, quality and efficacy of the product are not compromised, and that in all the circumstances of the case the product should be placed on the market.

(3) This paragraph does not apply in relation to a product recognised in more than one member State.

(4) In this paragraph a biological veterinary medicinal product is a veterinary medicinal product, the active substance of which is a biological substance; and a biological substance is a substance that is produced by or extracted from a biological source and for which a combination of physico-chemical-biological testing and the production process and its control is needed for its characterisation and the determination of its quality.

Commencement Information

I9 Sch. 1 para. 14 in force at 1.10.2006, see [reg. 1](#)

Similar immunological products

15. Where an immunological veterinary medicinal product is pharmacologically equivalent to a reference product other than differences in raw materials or in the manufacturing process, the results of the appropriate pre-clinical tests or clinical trials must be provided, but the applicant need not provide the results of safety tests or residue tests.

Commencement Information

I10 Sch. 1 para. 15 in force at 1.10.2006, see [reg. 1](#)

Marketing in exceptional circumstances

16. Where the health situation so requires, the Secretary of State may authorise the placing on the market of a veterinary medicinal product that has been authorised by another member State or, if there is no such authorised product, authorised in a third country.

Commencement Information

I11 Sch. 1 para. 16 in force at 1.10.2006, see [reg. 1](#)

Changes to legislation:

There are currently no known outstanding effects for the The Veterinary Medicines Regulations 2006, PART 2.